Kodiak Sciences Inc.
NASDAQ:KOD
Overview | Financials
Company Name | Kodiak Sciences Inc. |
Symbol | KOD |
Currency | USD |
Price | 9.25 |
Market Cap | 486,770,150 |
Dividend Yield | 0% |
52-week-range | 2.19 - 11.6 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Victor Perlroth M.D. |
Website | https://kodiak.com |
An error occurred while fetching data.
About Kodiak Sciences Inc.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD